WO2026012449 - HETEROCYCLIC COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT AND USE OF HETEROCYCLIC COMPOUND
National phase entry is expected:
Publication Number
WO/2026/012449
Publication Date
15.01.2026
International Application No.
PCT/CN2025/108008
International Filing Date
11.07.2025
Title **
[English]
HETEROCYCLIC COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT AND USE OF HETEROCYCLIC COMPOUND
[French]
COMPOSÉ HÉTÉROCYCLIQUE AYANT UN EFFET AGONISTE DU RÉCEPTEUR GLP-1 ET UTILISATION D'UN COMPOSÉ HÉTÉROCYCLIQUE
[Chinese]
一种具有GLP-1受体激动剂效应的杂环化合物及其应用
Applicants **
THE UNITED BIO-TECHNOLOGY (HENGQIN) CO., LTD.
ZHUHAI UNITED BIO-PHARMACEUTICAL CO., LTD
Inventors
GUO, Siyuan
HUANG, Liang
CAO, Chunlai
DENG, Huixing
XIE, Xin
LIU, Xiaoxiao
LIANG, Xiangchao
ZHANG, Jiaxin
MOU, Jianfeng
DUAN, Xinli
WANG, Tong
XUE, Sijing
SHI, Yingxin
YU, Qingfang
DENG, Xinyuan
Priority Data
202410937263.9
12.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2331 | |
| EPO | Filing, Examination, Granting | 17300 | |
| Japan | Filing, Examination, Granting | 2420 | |
| South Korea | Filing, Examination, Granting | 2647 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
30,038
Contact Us
Abstract[English]
The present invention relates to the field of medicines, and provides a heterocyclic compound having a GLP-1 receptor agonist effect and a use of the heterocyclic compound. The heterocyclic compound is a compound having a structure represented by formula (I), or an isomer, isotopically labeled compound, prodrug thereof, or a pharmaceutically acceptable salt, ester, hydrate, or solvate thereof: (I). The agonist can be used for treating metabolic syndromes and has a significant therapeutic effect in reducing blood glucose or losing weight.[French]
La présente invention relève du domaine des médicaments, et concerne un composé hétérocyclique ayant un effet agoniste du récepteur GLP-1 et une utilisation du composé hétérocyclique. Le composé hétérocyclique est un composé ayant une structure représentée par la formule (I), ou un isomère, un composé marqué isotopiquement, un promédicament de celui-ci, ou un sel, ester, hydrate ou solvate pharmaceutiquement acceptable de celui-ci : (I). L'agoniste peut être utilisé pour traiter des syndromes métaboliques et a un effet thérapeutique significatif dans la réduction du glucose sanguin ou la perte de poids.[Chinese]
涉及医药领域，提供了一种具有GLP-1受体激动剂效应的杂环化合物及其应用，其为式(Ⅰ)所示结构的化合物，或其异构体、同位素标记化合物、前药，或其药学上可接受的盐、酯、水合物或溶剂合物：，所述激动剂可用于治疗代谢综合症，在降糖或减重方面具有显著的治疗效果。